Results of the combined TNM III + IV cohort (n = 29) showed that high TF expression displayed a trend for hyperactive P-ERK and P-AKT signaling and an immune-tolerant tumor microenvironment as shown by an enriched presence of CD206+ M2-like macrophage and diminished levels of GZMB+CD8+ T cells, especially in patients with stages III and IV (Fig. 1F–I, Fig. S2A). The gene discussed is AKT1; the disease is neoplasm.